The treatment effect of Benzbromarone in acute ischemic cerebral vascular disease and its mechanisms

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16008313

Enrollment

Unknown

Registered

2016-04-19

Start date

2016-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic cerebral vascular disease

Interventions

Benzbromarone group:Benzbromarone and Common treatment

Contral group:Common treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. All patients must meet the diagnostic criteria for the Fourth National Conference on Cerebrovascular Disease legislature, and by CT and (or) MRI examination be confirmed with acute ischemic cerebrovascular disease (including transient ischemic attack); 2. onset within 24 hours; 3. blood uric acid level M> 420umol/L (7mg/dl), F> 357umol/L (6mg/dl) and no attack of gout.

Exclusion criteria

Exclusion criteria: 1. coma or NIHSS score> 20 points; 2. with cerebral aneurysms or arteriovenous malformations; 3. associated with traumatic brain injury history, history of stroke, SAH and a history of brain tumors; 4. with severe liver and kidney dysfunction, blood disorders or cancer; 5. 4 weeks of taking over iron or vitamin C and other antioxidants; 6. Other clinical studies within 3 months participated; 7. benzbromarone allergy.

Design outcomes

Primary

Measure	Time frame
NIHSS score;Barthel index;severity of carotid atherosclerosis;	—

Countries

China

Contacts

Public ContactFenghua Pan

The Second Affiliated Hospital of Nanjing Medical University

pfh1085@163.com+86 18951762884

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026